
Uncovering the Power of Pemvidutide: Altimmune’s Latest Lipidomic Findings to be Revealed at The Liver Meeting 2024
New Data Shows Promising Results from Altimmune’s Pemvidutide Treatment Overview Altimmune, Inc. has recently announced new data that demonstrates reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide. This exciting development will be presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD)…